Table of Content

1. Scope and Methodology
1.1. Research Methodology
1.2. Scope of the market

2. Key Trends and Developments
2.1. Key Trends and Developments

3. Executive Summary
3.1. Market Snippet By Drug Class
3.2. Market Snippet By Depression Disorder
3.3. Market Snippet By Region
3.4. DataM CLO Scenario

4. Market Dynamics
4.1. Market impacting factors
4.2. Drivers
4.2.1. Increase in prevalence of depression
4.2.2. Rise in geriatric population
4.2.3. Driver 3
4.3. Restraints
4.3.1. Preference of non-pharmacological therapies over pharmacological therapies
4.3.2. Restraint 2
4.4. Opportunity

5. Impact analysis

6. Industry Analysis
6.1. Porter’s five forces analysis
6.2. Epidemiology Analysis
6.3. Pipeline analysis

7. By Drug Class
7.1. Introduction
7.2. Market size analysis, and y-o-y growth analysis (%), By Drug Class segment
7.3. Market attractiveness index, By Drug Class segment
7.4. Monoamine oxidase inhibitors (MAOIs)
7.4.1. Introduction
7.4.2. Market size analysis, y-o-y growth analysis (%)
7.5. Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)
7.6. Serotonin-norepinephrine reuptake inhibitors (SNRIs)
7.7. Selective serotonin reuptake inhibitors (SSRIs)
7.8. Tricyclic antidepressants (TCAs)
7.9. Others

8. By Depression Disorder
8.1. Introduction
8.2. Market size analysis, and y-o-y growth analysis (%), By Depression Disorder segment
8.3. Market attractiveness index, By Depression Disorder segment
8.4. Major depressive disorder
8.4.1. Introduction
8.4.2. Market size analysis, and y-o-y growth analysis (%)
8.5. Obsessive-compulsive disorder
8.6. Generalized anxiety disorder
8.7. Panic disorder
8.8. Others

9. By Region
9.1. Introduction
9.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
9.4.1. Introduction
9.4.2. Key region-specific dynamics
9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder
9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.4.5.1. U.S.
9.4.5.2. Canada
9.4.5.3. Mexico
9.5. Europe
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder
9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.5.5.1. Germany
9.5.5.2. U.K.
9.5.5.3. France
9.5.5.4. Italy
9.5.5.5. Spain
9.5.5.6. Rest of Europe
9.6. South America
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder
9.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.6.5.1. Brazil
9.6.5.2. Argentina
9.6.5.3. Rest of South America
9.7. Asia Pacific
9.7.1. Introduction
9.7.2. Key Region-Specific Dynamics
9.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class
9.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder
9.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
9.7.5.1. China
9.7.5.2. India
9.7.5.3. Japan
9.7.5.4. Australia
9.7.5.5. Rest of Asia Pacific
9.8. The Middle East And Africa
9.8.1. Introduction
9.8.2. Key Region-Specific Dynamics
9.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class
9.8.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder

10. Competitive Landscape
10.1. Competitive scenario
10.2. Market positioning/share analysis
10.3. Comparative type portfolio analysis
10.4. Mergers and acquisitions analysis

11. Company Profiles
11.1. Allergan plc.
11.1.1. Company Overview
11.1.2. Type Portfolio And Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. AstraZeneca PLC
11.3. GlaxoSmithKline plc
11.4. Pfizer Inc.
11.5. Eli Lilly & Company Ltd.
11.6. Johnson & Johnson
11.7. Takeda Pharmaceutical Co. Ltd.
11.8. H. Lundbeck AS
11.9. Otsuka Holdings Co., Ltd.
11.10. Novartis AG

12. Premium Insights

13. DataM Intelligence
13.1. Appendix
13.2. About us and services
13.3. Contact us